In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
Lexology Index recognizes 44 CRA competition experts globally
This year, 44 CRA experts were named among the leading Competition Economists, with four recognized as Competition Future Leaders – Economists. This...